Le Lézard
Classified in: Health
Subject: RCL

Sunstar Americas, Inc. Issues Voluntary Nationwide Recall of GUM® Hydral Dry Mouth Relief Oral Spray Due to Possible Microbial Contamination


CHICAGO, Feb. 18, 2021 /PRNewswire/ -- Sunstar Americas, Inc. (SAI) is voluntarily recalling GUM® Hydral Dry Mouth Relief Oral Spray products bearing an expiration date from 2021-11 through 2022-05 (see specific lots below) to the consumer level.  This product may be contaminated with the bacteria Burkholderia cepacia.

Use of the defective product in the immunocompetent host may result in oral and, potentially, systemic infections requiring antibacterial therapy.  In the most at-risk populations, the use of the defective product may result in life-threatening infections, such as pneumonia and bacteremia.  To date, no adverse events have been reported to SAI related to this recall.

The oral spray, available through retail, is indicated for use for lubricating, moisturizing, soothing, and refreshing properties to help relieve and manage the symptoms of dry mouth:

GUM® Hydral Dry Mouth Relief Oral Spray was distributed Nationwide to Grocery and Drug Wholesalers, Grocery and Drug chains, Web distribution and sales, and direct to consumers.

SAI is notifying its direct distributors and customers by USPS Priority mail and is arranging for return of all recalled products.  Patients, pharmacies, and healthcare facilities in possession of these products should stop using and dispensing immediately.

Consumers with questions regarding this recall can contact SAI by phone at 1-800-528-8537 or email [email protected] on Monday-Friday from 8am-5pm CST.  Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product.

Affected products and lot numbers follow below:

AFFECTED LOTS

SKU#

Lot

Exp

1800R

493538

2021/11

1800R

493539

2021/11

1800R

493540

2021/11

1800R

493541

2021/12

1800R

498339

2021/12

1800R

498340

2021/12

1800R

498341

2021/12

1800R

498342

2021/12

1800R

511571

2022/01

1800R

516383

2022/02

1800R

516384

2022/02

1800RA

C140DD

2022-05

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Sunstar is committed to delivering safe, fully compliant products of the highest quality and is taking necessary steps to prevent future occurrence of this issue.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

About Sunstar Americas, Inc.

Sunstar Americas, Inc., a member of the Sunstar Group of companies, is a global organization headquartered in Switzerland that is a leader in the oral care industry and the manufacturer and distributor of the GUM and Butler Brands.

For more information:

Company Contact:
Greg Belair
847-794-4241
[email protected]

Contact us:
Phone: 1-800-528-8537
Email: [email protected]

Visit us at: https://www.gumbrand.com/news-announcements

 

SOURCE Sunstar Americas, Inc.


These press releases may also interest you

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The report titled "Anti-Adhesion Products Market by Product Type (Natural Adhesion Barriers, Synthetic Adhesion Barriers), Product Form (Film Formulation, Gel Formulation, Liquid Formulation), Application, End-User - Global Forecast 2024-2030" is now...

25 avr 2024
Product: Meat and vegetable products Issue: Food - Microbial Contamination - Listeria Distribution:British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

25 avr 2024
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...



News published on and distributed by: